MD Anderson Cancer Center President Peter W.T. Pisters challenged Selwyn M. Vickers, president and CEO of Memorial Sloan Kettering Cancer Center, to a friendly Twitter bet.
Researchers from Memorial Sloan Kettering Cancer Center have discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future AML relapse from others present after treatment using Mission Bio Inc.’s Tapestri Single-cell Multi-omics Measurable Residual Disease assay.
Researchers have compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.
Don’t sack the director because your cancer center’s score and ranking by U.S. News & World Report have slipped.
Two years ago, as next-generation sequencing and checkpoint inhibitors became the standard of care in many cancers, Joan Massagué started hearing questions from philanthropists about the “next big thing” in cancer research.
The past two decades have been a golden age of discovery in genetics and cancer research. Using fast, affordable DNA sequencing, scientists have identified scores of gene mutations associated with cancer and developed highly effective drugs to target them.
Selwyn M. Vickers was named president and chief executive officer of Memorial Sloan Kettering Cancer Center.
The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.
All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery.
Last week, I became obsessed with reports that Vladimir Putin is a believer in an unproven remedy that involves bathing in blood drained from the horns of Siberian red deer.
